Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow

Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV combo hits primary endpoint in two Phase 3 trials.